Cannaxan GmbH

4 trials Commercial sponsor

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

0 Recruiting

4 Completed trials

2 Countries active

22 Unique IMPs

100% Results reported

Phase III

Oversight events:

8 temporary halts 4 corrective measures across 4 trials

View oversight register →

100%

4 of 4 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top IMPs

All trials

4 total

Efficacy and Tolerability of AP707 in Patients with chronic Pain due to Diabetic Polyneuropathy Ended

2022-500897-32-00 Phase III 2 countries ADEZUNAP
Efficacy and Tolerability of AP707 in Patients with chronic Pain due to traumatic or post-operative peripheral Neuropathy Ended

2022-500898-13-00 Phase III 2 countries ADEZUNAP
Efficacy and Tolerability of AP707 in Patients with chronic pain due to central Neuropathy of any Genesis Ended

2022-500899-66-00 Phase III 2 countries ADEZUNAP
Efficacy and Tolerability of AP707 in Patients with Chronic Back Pain Ended

2022-502151-54-00 Phase III 2 countries ADEZUNAP

Showing 1–4 of 4 trials

← All sponsors A–Z